MoonLake Immunotherapeutics Reports Full Year 2024 Financial Results and Provides a Business Update
Initiated the Phase 3 VELA program of the Nanobody® sonelokimab in patients with moderate-to-severe hidradenitis suppurativa (HS) and the Phase 3 ...
Drug companies and Minister agree medicines need to be available to patients more quickly
Patients should have faster access to newly developed drugs and medicines and the Government is prepared to adopt new ...
Gov13h
PBBM vows to lower the cost of medicine to a true generic level similar to India
Unfortunately, not even the implementation of the Generics Act of 1988, also known as Republic Act No. 6675, or a law that aims to produce affordable but effective medicines available to the public, ...
Global Advanced Therapy Medicinal Products Market to Grow Immensely at a CAGR of ~14% by 2032 | DelveInsight
DelveInsight's Advanced Therapy Medicinal Products Market Insights report provides the current and forecast market analysis, ...
Hosted on MSN19h
EMA approves Takeda’s Takhzyro pre-filled pen option for HAE
The European Medicines Agency (EMA) has approved an additional 2 mL pre-filled pen option for subcutaneous administration of ...
centerforbiosimilars19h
Biosimilar Approvals Streamlined With Advanced Statistics Amidst Differing Regulatory Requirements
The FDA and European Medicines Agency (EMA) mandate high similarity between biosimilars and reference products, but their ...
Hosted on MSN21h
Gilead’s lenacapavir applications for HIV gain EMA validation
Gilead Sciences has announced the European Medicines Agency’s (EMA) validation for a parallel accelerated review of ...